嗜酸粒细胞性哮喘生物标志物的研究进展  

Advances in biomarkers for eosinophilic asthma

作　　者：陈雪琴 张明顺[2,3] 黄茂 吉宁飞 CHEN Xueqin;ZHANG Mingshun;HUANG Mao;JI Ningfei(Department of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029;Key Laboratory of Antibody Techniques of National Health Commission,Nanjing Medical University,Nanjing 211166,China;Department of Immunology,Nanjing Medical University,Nanjing 211166,China)

机构地区：[1]南京医科大学第一附属医院呼吸与危重症医学科,江苏南京210029 [2]南京医科大学国家卫生健康委员会抗体技术重点实验室,江苏南京2111663 [3]南京医科大学免疫学系,江苏南京2111663

出　　处：《南京医科大学学报（自然科学版）》2022年第5期734-739,共6页Journal of Nanjing Medical University(Natural Sciences)

基　　金：国家自然科学基金面上项目(81770031,81970031)。

摘　　要：哮喘是一种以慢性气道炎症为特点的异质性疾病,而嗜酸粒细胞性哮喘是基于气道炎症分型中最常见的一种亚型。作为诱导痰的替代生物标志物,血嗜酸粒细胞、呼出气一氧化氮、血清骨膜蛋白等被广泛应用于嗜酸粒细胞性哮喘的研究,但这些生物标志物预测嗜酸性气道炎症的能力饱受争议,联合使用或许能提高诊断的准确度。此外,随着组学技术的开展以及对疾病发病机制的深入认识,未来新型生物标志物有望应用于临床。Asthma is a heterogeneous disease characterized by chronic airway inflammation.Eosinophilic asthma is the most common subtype based on airway inflammatory classification.As alternative biomarkers for induced sputum,blood eosinophil,fractional exhaled nitric oxide,and serum periostin have been widely used in the study of eosinophilic asthma,but their ability to predict eosinophilic airway inflammation is controversial.Combined use of two or more biomarkers may improve the accuracy of diagnosis.In addition,with the development of omics technology and the in-depth understanding of the pathogenesis of asthma,new biomarkers are expected to be applied in clinic in the future.

关 键 词：嗜酸粒细胞性哮喘 生物标志物 血嗜酸粒细胞 呼出气一氧化氮 组学 

分 类 号：R562.25[医药卫生—呼吸系统]